Stay updated with the latest news, product updates, research insights, and important announcements from Generic Peptides.
After Ozempic, FDA's Next Peptide Fight Is Here: PSM Opposes All Seven Substances The deadline for comments guaranteed to reach the advisory committee has passed. BPC-157, TB-500, MOTS-c, Semax and three other peptides now face a decision that could close the…
FDA Staff Recommends Against All Seven Peptides Before July PCAC Vote: Why That May Be a Bad Idea Reading Time: 6 mins Regulatory News · FDA · PCAC · Peptide Compounding · 503A Bulks List By Generic Peptides Team FDA staff has now taken the clearest possible …
Epitalon and the FDA: Can the Insomnia Nomination Survive Scientific Review? By the Generic Peptides Team Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article explains a public regulatory proceeding and is not medical or…
Semax Before the FDA: Cerebral Ischemia, Migraine and Trigeminal Neuralgia By the Generic Peptides Team Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article covers a public regulatory proceeding and is not medical or leg…
DSIP or Emideltide: Why FDA Is Reviewing the "Sleep Peptide" By the Generic Peptides Team Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article explains a public regulatory proceeding and is not medical or legal advice. E…
MOTS-c at the FDA: Obesity, Osteoporosis and the Missing Human Evidence By the Generic Peptides Team Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article explains a public regulatory proceeding and is not medical or lega…
TB-500 Faces FDA Review: The Evidence Behind Its Wound-Healing Nomination By the Generic Peptides Team Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article explains a public regulatory proceeding and is not medical or le…
KPV and the FDA: Why Wound Healing and Inflammation Are Under Review By the Generic Peptides Team Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article explains a public regulatory proceeding and is not medical or legal a…
BPC-157 Goes Before the FDA: What the July 2026 Review Actually Means By the Generic Peptides Team Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article explains a public regulatory proceeding and is not medical or legal …
FDA Peptide Meeting July 2026: Seven Peptides, Two Days, and What Could Change By Generic Peptides Team Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article explains a public regulatory proceeding and is not medical or l…
The Peptide Boom Is Here: Why Buyers Are Looking Beyond GLP-1s in 2026 By Generic Peptides Team Peptides are no longer a niche topic hidden inside bodybuilding forums, longevity podcasts, or private biohacking groups. In 2026, they have moved into the center …
Pemvidutide's 48-Week Data: A Real MASH Contender — or Just Another Phase 2 Headline? What Altimmune Just Showed at EASL On May 28, 2026, at the European Association for the Study of the Liver (EASL) Congress in Barcelona, Altimmune unveiled the full 48-week …